Literature DB >> 15317673

Chronic hypoxia induces nonreversible right ventricle dysfunction and dysplasia in rats.

Pierre Bonnet1, Sébastien Bonnet, Julien Boissière, Jean-Loïc Le Net, Mathieu Gautier, Eric Dumas de la Roque, Véronique Eder.   

Abstract

The purpose of this study was to evaluate the reversibility of right ventricular (RV) remodelling after pulmonary artery hypertension (PAHT) secondary to 3 wk of hypobaric hypoxia. A group of 10 adult male Wistar rats were studied and were the following: control normoxic (C), after 3 wk of chronic hypoxia (CH), and after 3 wk of exposure to hypoxia followed by 3 wk of normoxia recovery (N-RE). Mean pulmonary artery pressure was 11 +/- 2 mmHg in the C group, 35 +/- 2 mmHg in the CH group, and 14 +/- 3 mmHg in the N-RE group. RV function was assessed by echocardiography. In the CH group, the pulmonary flow measured in Doppler mode depicted a midsystolic notch and a decrease of the pulmonary acceleration time compared with control [17 +/- 1 vs. 34 +/- 1 ms (n = 10), respectively; P < 0.05]. RV thickening measured in M-mode was apparent in the CH group compared with the control group [2.84 +/- 0.40 vs. 1.73 +/- 0.26 mm (n = 10), P < 0.05]. In the N-RE group, the RV wall was significantly thinner compared with the CH group [1.56 +/- 0.08 vs. 1.73 +/- 0.26 mm (n = 10), P < 0.05]. The calculated RV diameter shortness fraction was not different between the CH group and C group (34 +/- 4.2% vs. 36 +/- 2.8%) but decreased in the N-RE group [20 +/- 2.4% (n = 10), P < 0.01]. The E-to-A wave ratio on the tricuspid Doppler inflow was significantly lower in the CH group and N-RE group compared with the C group [0.70 +/- 0.8 and 0.72 +/- 0.1 vs. 0.88 +/- 0.2 (n = 10), respectively; P < 0.05]. In the isolated perfused heart using the Langendorff method, RV compliance was increased in the CH group and decreased in the N-RE group. In the N-RE group, fibrous bands with metaplasia were observed on histological sections of the RV free wall. We conclude that PAHT induces nonreversible RV dysfunction with dysplasia.

Entities:  

Mesh:

Year:  2004        PMID: 15317673     DOI: 10.1152/ajpheart.00802.2003

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  5 in total

1.  The Sugen 5416/hypoxia mouse model of pulmonary hypertension revisited: long-term follow-up.

Authors:  Sally H Vitali; Georg Hansmann; Chase Rose; Angeles Fernandez-Gonzalez; Annette Scheid; S Alex Mitsialis; Stella Kourembanas
Journal:  Pulm Circ       Date:  2014-12       Impact factor: 3.017

2.  Increased TMEM16A-encoded calcium-activated chloride channel activity is associated with pulmonary hypertension.

Authors:  Abigail S Forrest; Talia C Joyce; Marissa L Huebner; Ramon J Ayon; Michael Wiwchar; John Joyce; Natalie Freitas; Alison J Davis; Linda Ye; Dayue D Duan; Cherie A Singer; Maria L Valencik; Iain A Greenwood; Normand Leblanc
Journal:  Am J Physiol Cell Physiol       Date:  2012-10-03       Impact factor: 4.249

3.  Therapeutic efficacy of TBC3711 in monocrotaline-induced pulmonary hypertension.

Authors:  Djuro Kosanovic; Baktybek Kojonazarov; Himal Luitel; Bhola K Dahal; Akylbek Sydykov; Teodora Cornitescu; Wiebke Janssen; Ralf P Brandes; Neil Davie; Hossein A Ghofrani; Norbert Weissmann; Friedrich Grimminger; Werner Seeger; Ralph T Schermuly
Journal:  Respir Res       Date:  2011-06-23

4.  Influence of hypoxia on the domiciliation of mesenchymal stem cells after infusion into rats: possibilities of targeting pulmonary artery remodeling via cells therapies?

Authors:  Gaël Y Rochefort; Pascal Vaudin; Nicolas Bonnet; Jean-Christophe Pages; Jorge Domenech; Pierre Charbord; Véronique Eder
Journal:  Respir Res       Date:  2005-10-27

5.  Echocardiographic markers of pulmonary hemodynamics and right ventricular hypertrophy in rat models of pulmonary hypertension.

Authors:  Fotios Spyropoulos; Sally H Vitali; Marlin Touma; Chase D Rose; Carter R Petty; Philip Levy; Stella Kourembanas; Helen Christou
Journal:  Pulm Circ       Date:  2020-05-29       Impact factor: 3.017

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.